Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

VHL Antikörper

VHL Reaktivität: Human, Maus, Ratte IHC, IF Wirt: Kaninchen Polyclonal unconjugated
Produktnummer ABIN7254899
  • Target Alle VHL Antikörper anzeigen
    VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
    Reaktivität
    • 61
    • 37
    • 34
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Human, Maus, Ratte
    Wirt
    • 64
    • 13
    • 2
    Kaninchen
    Klonalität
    • 69
    • 10
    Polyklonal
    Konjugat
    • 41
    • 5
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    Dieser VHL Antikörper ist unkonjugiert
    Applikation
    • 47
    • 27
    • 26
    • 26
    • 19
    • 16
    • 12
    • 8
    • 6
    • 4
    • 3
    • 2
    • 2
    • 1
    • 1
    Immunohistochemistry (IHC), Immunofluorescence (IF)
    Produktmerkmale
    Polyclonal Antibody
    Aufreinigung
    Affinity purification
    Immunogen
    Recombinant fusion protein of human VHL (NP_937799.1).
    Isotyp
    IgG
    Top Product
    Discover our top product VHL Primärantikörper
  • Applikationshinweise
    IHC 1:50-1:200 IF 1:50-1:200
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    1 mg/mL
    Buffer
    PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    -20 °C
    Informationen zur Lagerung
    Store at -20°C. Avoid freeze / thaw cycles.
  • Target
    VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
    Andere Bezeichnung
    VHL (VHL Produkte)
    Synonyme
    HRCA1 antikoerper, RCA1 antikoerper, VHL1 antikoerper, pVHL antikoerper, BcDNA:RH61560 antikoerper, CG13221 antikoerper, DVhl antikoerper, Dmel\\CG13221 antikoerper, Dvhl antikoerper, VHL antikoerper, d-VHL antikoerper, d-vhl antikoerper, dVHL antikoerper, dmVHL antikoerper, vhl antikoerper, rca1 antikoerper, vhl1 antikoerper, hrca1 antikoerper, zgc:158722 antikoerper, Vhlh antikoerper, von Hippel-Lindau tumor suppressor antikoerper, von Hippel-Lindau antikoerper, von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase antikoerper, von Hippel-Lindau disease tumor suppressor antikoerper, VHL antikoerper, Vhl antikoerper, vhl antikoerper, CpipJ_CPIJ009992 antikoerper
    Hintergrund
    Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.
    Gen-ID
    7428
    UniProt
    P40337
    Pathways
    Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Ubiquitin Proteasome Pathway
Sie sind hier:
Kundenservice